Trial reportAfrican health sciences2024
The effect of radio-frequency ablation in treating pulmonary ground glass nodule patients and its influence on pulmonary function.
Trial report in African health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Research status and trend of lung cancer ablation therapy: a bibliometric analysis from 2002 to 2025.Journal of thoracic disease · 2026Article
- Changes in Respiratory Function over Time after Radiofrequency Ablation for Lung Tumors.Interventional radiology (Higashimatsuyama-shi (Japan) · 2026Article
- Editor's choice: Infections, sexual reproductive health and non-communicable diseases.African health sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: With widespread application of low-dose thin-section chest CT screening, the detection rate of patients with subsolid nodules (SNs) as CT findings has increased remarkably. Objective: To clarify effect of radio-frequency ablation (RFA) in treating pulmonary ground glass nodule (GGN) patients and its impact on pulmonary function. Methods: A total of 100 patients diagnosed with pulmonary GGN in our hospital from January 2019 to December 2021 by pulmonary thin-section CT + enhanced imaging examination and all underwent simultaneous needle biopsy were enrolled and randomly divided into control group and observation group, with 50 cases each. The control group received treatment with traditional surgery. The observation group received treatment with RFA. The surgical indicators, surgical treatment efficacy, levels of inflammatory cytokines, complications and pulmonary function indicators were assessed between two groups. Results: The operation time, hospital stay and intraoperative blood loss in observation group were markedly shorter/less than controls (P < 0.05). No residual recurrence was observed in total 84 nodules of 50 cases in observation group. The size of nodules was observed by CT 1, 3 and 6 months after operation. With prolongation of postoperative time, nodules gradually shrank, after 6 months, fibrous cord scar residue gradually formed, with statistical significance relative to those before operation (P < 0.05). The postoperative IL-6, CRP and TNF-α in both groups presented elevation, whereas postoperative changes in IL-6, CRP and TNF-α in observation group presented depletion relative to control group, with statistical significance (P < 0.05). The complication rate in observation group presented depletion relative to control group, with statistical significance (P < 0.05). The FVC, FEV1, FEV1%, MVV and PEF in both groups presented depletion 1 month after operation and presented statistical significance relative to those before operation except for FEV1% (P < 0.05), and changes in observation group presented depletion relative to control group. Six months after operation, FVC, FEV1, FEV1%, MVV and PEF in both groups had recovered to preoperative levels and presented no difference relative to preoperative level (P > 0.05), and presented no difference between two groups (P > 0.05). Conclusion: RFA for the therapy of pulmonary GGN is safe and effective, without surgical scar, and is less traumatic to the body, which has a good application prospect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.